EGFR and non-small cell lung carcinoma: In conclusion, our results demonstrate that BIM is essential for gefitinib-induced killing of NSCLC cells expressing mutant EGFR. Shutdown of the MEK–ERK1/2 pathway appears critical for BIM up-regulation, but other signaling pathways may also contribute.